Brachytherapy for prostate cancer

Atsunori Yorozu, Kazuhito Toya, Toshio Ohashi, Kae Ohsuga, Reiko Ito, Tomotaka Kasamatsu, Shiro Saito, Tetsuo Momma

研究成果: Article

3 引用 (Scopus)

抄録

This review article aims to overview modern prostate brachytherapy in Japan. Permanent transperineal prostate brachytherapy with I-125 started in September, 2003 in Japan. Brachytherapy has several advantages: the dose is adapted precisely to the tumor shape and size, and the long-lived isotope gives a higher tumor dose with less damage to normal tissue; less-time consuming for patients and staff: long-term results comparable to surgery or external beam series in the USA; and quality of life after brachytherapy also appealing. These advantages have brought about increasing use in Japan as well. Patients with a high probability of organ-confined disease and a low-risk group are appropriately treated with brachytherapy. Brachytherapy candidates with a significant risk of extraprostatic extension should be treated with supplemental external beam radiation therapy. High-dose-rate (HDR) brachytherapy with Ir-192 has preceded seed implants in Japan. HDR has some theoretical advantages. Long-term results of brachytherapy in the USA are comparable with surgery or external beam irradiation so far. We should develop more sophisticated brachytherapy techniques in Japan.

元の言語English
ページ(範囲)424-427
ページ数4
ジャーナルGan to kagaku ryoho. Cancer & chemotherapy.
33
発行部数4
出版物ステータスPublished - 2006 4
外部発表Yes

Fingerprint

Brachytherapy
Prostatic Neoplasms
Japan
Prostate
Isotopes
Neoplasms
Seeds
Radiotherapy
Quality of Life

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

これを引用

Yorozu, A., Toya, K., Ohashi, T., Ohsuga, K., Ito, R., Kasamatsu, T., ... Momma, T. (2006). Brachytherapy for prostate cancer. Gan to kagaku ryoho. Cancer & chemotherapy., 33(4), 424-427.

Brachytherapy for prostate cancer. / Yorozu, Atsunori; Toya, Kazuhito; Ohashi, Toshio; Ohsuga, Kae; Ito, Reiko; Kasamatsu, Tomotaka; Saito, Shiro; Momma, Tetsuo.

:: Gan to kagaku ryoho. Cancer & chemotherapy., 巻 33, 番号 4, 04.2006, p. 424-427.

研究成果: Article

Yorozu, A, Toya, K, Ohashi, T, Ohsuga, K, Ito, R, Kasamatsu, T, Saito, S & Momma, T 2006, 'Brachytherapy for prostate cancer', Gan to kagaku ryoho. Cancer & chemotherapy., 巻. 33, 番号 4, pp. 424-427.
Yorozu A, Toya K, Ohashi T, Ohsuga K, Ito R, Kasamatsu T その他. Brachytherapy for prostate cancer. Gan to kagaku ryoho. Cancer & chemotherapy. 2006 4;33(4):424-427.
Yorozu, Atsunori ; Toya, Kazuhito ; Ohashi, Toshio ; Ohsuga, Kae ; Ito, Reiko ; Kasamatsu, Tomotaka ; Saito, Shiro ; Momma, Tetsuo. / Brachytherapy for prostate cancer. :: Gan to kagaku ryoho. Cancer & chemotherapy. 2006 ; 巻 33, 番号 4. pp. 424-427.
@article{9000aa6c4275403694b72de0ab06af34,
title = "Brachytherapy for prostate cancer",
abstract = "This review article aims to overview modern prostate brachytherapy in Japan. Permanent transperineal prostate brachytherapy with I-125 started in September, 2003 in Japan. Brachytherapy has several advantages: the dose is adapted precisely to the tumor shape and size, and the long-lived isotope gives a higher tumor dose with less damage to normal tissue; less-time consuming for patients and staff: long-term results comparable to surgery or external beam series in the USA; and quality of life after brachytherapy also appealing. These advantages have brought about increasing use in Japan as well. Patients with a high probability of organ-confined disease and a low-risk group are appropriately treated with brachytherapy. Brachytherapy candidates with a significant risk of extraprostatic extension should be treated with supplemental external beam radiation therapy. High-dose-rate (HDR) brachytherapy with Ir-192 has preceded seed implants in Japan. HDR has some theoretical advantages. Long-term results of brachytherapy in the USA are comparable with surgery or external beam irradiation so far. We should develop more sophisticated brachytherapy techniques in Japan.",
author = "Atsunori Yorozu and Kazuhito Toya and Toshio Ohashi and Kae Ohsuga and Reiko Ito and Tomotaka Kasamatsu and Shiro Saito and Tetsuo Momma",
year = "2006",
month = "4",
language = "English",
volume = "33",
pages = "424--427",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "4",

}

TY - JOUR

T1 - Brachytherapy for prostate cancer

AU - Yorozu, Atsunori

AU - Toya, Kazuhito

AU - Ohashi, Toshio

AU - Ohsuga, Kae

AU - Ito, Reiko

AU - Kasamatsu, Tomotaka

AU - Saito, Shiro

AU - Momma, Tetsuo

PY - 2006/4

Y1 - 2006/4

N2 - This review article aims to overview modern prostate brachytherapy in Japan. Permanent transperineal prostate brachytherapy with I-125 started in September, 2003 in Japan. Brachytherapy has several advantages: the dose is adapted precisely to the tumor shape and size, and the long-lived isotope gives a higher tumor dose with less damage to normal tissue; less-time consuming for patients and staff: long-term results comparable to surgery or external beam series in the USA; and quality of life after brachytherapy also appealing. These advantages have brought about increasing use in Japan as well. Patients with a high probability of organ-confined disease and a low-risk group are appropriately treated with brachytherapy. Brachytherapy candidates with a significant risk of extraprostatic extension should be treated with supplemental external beam radiation therapy. High-dose-rate (HDR) brachytherapy with Ir-192 has preceded seed implants in Japan. HDR has some theoretical advantages. Long-term results of brachytherapy in the USA are comparable with surgery or external beam irradiation so far. We should develop more sophisticated brachytherapy techniques in Japan.

AB - This review article aims to overview modern prostate brachytherapy in Japan. Permanent transperineal prostate brachytherapy with I-125 started in September, 2003 in Japan. Brachytherapy has several advantages: the dose is adapted precisely to the tumor shape and size, and the long-lived isotope gives a higher tumor dose with less damage to normal tissue; less-time consuming for patients and staff: long-term results comparable to surgery or external beam series in the USA; and quality of life after brachytherapy also appealing. These advantages have brought about increasing use in Japan as well. Patients with a high probability of organ-confined disease and a low-risk group are appropriately treated with brachytherapy. Brachytherapy candidates with a significant risk of extraprostatic extension should be treated with supplemental external beam radiation therapy. High-dose-rate (HDR) brachytherapy with Ir-192 has preceded seed implants in Japan. HDR has some theoretical advantages. Long-term results of brachytherapy in the USA are comparable with surgery or external beam irradiation so far. We should develop more sophisticated brachytherapy techniques in Japan.

UR - http://www.scopus.com/inward/record.url?scp=33646359191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646359191&partnerID=8YFLogxK

M3 - Article

C2 - 16612148

AN - SCOPUS:33646359191

VL - 33

SP - 424

EP - 427

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 4

ER -